Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Small-molecule GSK-3 inhibitor stimulates bone formation in vitro and in vivo

Oct. 13, 2004

Two series of PTP inhibitors presented by TransTech researchers

Oct. 13, 2004

MRL-123 decreases bone resorption and increases BMD in osteoporotic women

Oct. 11, 2004

One-year treatment with ED-71 increases bone mineral density in osteoporotic patients

Oct. 8, 2004

AMG-162 increases bone density of postmenopausal women with osteoporosis

Oct. 8, 2004

Positive results from Lab International's phase I/II study of GHRH analogue

Oct. 8, 2004

Women with polycystic ovary syndrome are at a greater risk for developing diabetes and heart disease

Oct. 8, 2004

Strontium ranelate reported to reduce fracture risk in very elderly osteoporotic women

Oct. 8, 2004

Phase I study for Hematide

Oct. 7, 2004

ConjuChem updates progress of DAC:GLP-1 development

Oct. 7, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Recludix’s first-in-class STAT6 inhibitor shows efficacy in atopic dermatitis
BioWorld Science
Researchers from Recludix Pharma Inc. reported preclinical efficacy data on REX-8756 (SAR-448755), a first-in-class orthosteric STAT6 inhibitor in models of...